Skip to main content

Table 2 Baseline characteristics of 14 comparative studies and patients

From: Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Authors (year) [Ref] Study Design Region Patients CPS BCLC ECOG Aetiology Treatment Quality Assessment
Martin et al. (2010) a [43] Prospective several countries 150 ST:B = 31% DT:B = 39% NA NA NA ST, n = 30; DT, n = 120. 17
Kudo et al. (2011) [15] Phase III Randomized Japan 229 A = 100% NA 0 = 87% 1 = 13% HBV = 20% HCV = 60% Sorafenib was given 1–3 months after TACE till progression 18
South Korea
Sansonno et al. (2012) [44] Phase II prospective randomized Italy 40 A = 100% B = 100% 0 = 86% 1 = 24% HCV = 100% Sorafenib started 1 month after TACE till progression nor unacceptable toxicity 4
Lencioni et al. (2012) a [10] Phase II prospective randomized several countries 307 A = 100% B = 100% 0 = 100% NA Continuous sorafenib 3–7d before TACE 4
Qu et al. (2012) [45] Retrospective China 45 A = 65% B = 35% B = 35% C = 65% 0 = 95% 1 = 5% HBV = 100% Sorafenib started after TACE 17
Bai et al. (2013) [46] Prospective China 82 A = 77% B = 23% B = 23% C = 77% 0 = 36.5% 1 = 46.5% HBV = 87.9% HCV = 4.9% Continuous sorafenib started within 14d after TACE 19
2 = 14.6%
3 = 1.2%
4 = 1.2%
Muhammad et al. (2013) a [47] Retrospective USA 43 ST:A = 85% DT:A = 77% A = 46% B = 15% C = 38% NA ST:HCV = 69% DT:HCV = 93% Sorafenib started with 200 mg bid and then increased to 400 mg in the majority of patients 20
Huang et al. (2013) [48] Prospective China 155 NA NA NA NA Sorafenib started within 2 weeks of the first cycle of TACE 14
Hu et al. (2014) [14] Retrospective China 280 ST:A = 70.7% T:A = 67.7% B = 100% NA ST:HBV = 82.9% T:HBV = 79.8% Sorafenib after TACE 20
Ohki et al. (2015) [6] Retrospective Japan 95 ST:A = 70.8% T:A = 56.3% NA NA ST:HCV = 75.0% T:HCV = 67.6% Sorafenib was started within 2 weeks after TACE 17
Yao et al. (2016) [12] Prospective China 150 A = 84% B = 16% B = 42% C = 58% 0 = 42% 1 = 58% ST:HBV = 84% T:HBV = 83% Sorafenib therapy was initiated within 1 week before or after the initial TACE treatment 20
Zhang et al. (2016) [49] Retrospective China 20 A = 100% NA 0 = 85% 1 = 15% HBV = 80% Sorafenib was given with an interval of 4-7 days before or after TACE session 19
Wan et al. (2016) [50] Retrospective China 450 A = 87% B = 13% NA 0–1 = 91% 2 = 9% NA Oral sorafenib was administrated before or after TACE 14
Varghese et al. (2017) [13] Retrospective India 124 B:A = 55.9% B = 44.1% C:A = 46.2% B = 53.8% B = 47.6% C = 52.4% NA B:HBV = 37.3% HCV = 18.7% C:HBV = 26.2% HCV = 23% Sorafenib was introduced 5d after TACE 17
  1. Abbreviations: BCLC The Barcelona Clinic Liver Cancer, CPS Child-Pugh classification, ECOG Eastern Cooperative Oncology Group, NA not available, ST sorafenib plus TACE, DT DEB –TACE, HBV hepatitis B virus, HCV hepatitis C virus, MINORS methodological index for non-randomized studies
  2. a TACE with drug-eluting beads (DEB) was performed in the studies. Patients in other studies treated with conventional TACE (c-TACE). Quality assessment of RCT trial adopted Jadad scale. Scores of non-randomized experimental study were assessed by MINORS